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Activation of naiveCD4+ Tcells results in the development of several distinct subsets of effectorThcells, includingTh2cells that play
a pivotal role in allergic inflammation and helminthic infections. SWAP-70-like adapter of T cells (SLAT), also known as Def6 or
IBP, is a guanine nucleotide exchange factor for small GTPases, which regulates CD4+ T cell inflammatory responses by controlling
Ca2+/NFAT signaling. In this study, we have identified a novel alternatively spliced isoform of SLAT, named SLAT2, which lacks the
region encoded by exons 2–7 of theDef6 gene. SLAT2 was selectively expressed in differentiatedTh2 cells after the second round of
in vitro stimulation, but not in differentiated Th1, Th17, or regulatory T (Treg) cells. Functional assays revealed that SLAT2 shared
with SLAT the ability to enhance T cell receptor- (TCR-) mediated activation of NFAT and production of IL-4 but was unable to
enhance TCR-induced adhesion to ICAM-1. Ectopic expression of SLAT2 or SLAT in Jurkat T cells resulted in the expression of
distinct forms of filopodia, namely, short versus long ones, respectively. These results demonstrate that modulating either SLAT2
or SLAT protein expression could play critical roles in cytokine production and actin reorganization during inflammatory immune
responses.
1. Introduction
During inflammatory immune responses under local cytoki-
ne environment, naive CD4+ T cells differentiate into distinct
lineages including T helper 1 (Th1), Th2,Th17, and regulatory
T (Treg) cells [1]. Both TCR-derived signals and the cytokine
environment at the site of inflammatory immune responses
play an important role in the fate decisions ofTh subsets, and
several TCR-proximal signaling intermediates can regulate
Th subset differentiation [2]. Each Th cell subset expresses
a unique set of transcription factors and produces hallmark
cytokines [2], with Th2 cells being controlled by the master
transcription factor, GATA3. Differentiated Th2 cells secrete
IL-4, IL-5, and IL-13, which are important in inflammatory
asthma and atopy, and constitute a defense against extracel-
lular pathogens during inflammation. However, little infor-
mation exists with regard to TCR-proximal signaling events
that are unique to the differentiatedTh2 subset.
We have previously isolated and characterized a TCR-
regulated signaling protein termed SWAP-70-like adapter of
T cells (SLAT) [3] encoded by the Def6 gene and found
it to share homology with SWAP-70, which is involved
in B and mast cell activation [4–6] and to be expressed
predominantly inTh cells and thymocytes. SLAT, also known
as Def6 [7] or IBP [8], displays a guanine nucleotide
exchange factor (GEF) activity for the Cdc42 and Rac1
small GTPases [9–14]. The human homolog of SLAT, termed
IRF-4-binding protein (IBP), was independently isolated by
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another group [8]. Structurally, SLAT contains, beginning
at its N terminus, a Ca2+-binding EF-hand domain [15], an
immunoreceptor tyrosine-based activation motif- (ITAM-
) like sequence, a phosphatidylinositol 3,4,5-trisphosphate-
binding pleckstrin homology (PH) domain [3], and a catalytic
Dbl homology (DH) domain [9–14, 16]. Our previous study
ofDef6-deficient mice revealed SLAT to be a critical selective
regulator of the TCR-coupled Ca2+/NFAT signaling pathway,
controlling positively CD4+ Th cell activation and differen-
tiation, as evidenced by its critical role in the development
of T cell-dependent inflammatory diseases such as aller-
gic lung inflammation [17] and experimental autoimmune
encephalomyelitis [18].
Alternative splicing is a critical mechanism that regulates
gene expression at the posttranscriptional level. A number
of genes exhibit significant changes in isoform expression
during inflammatory immune responses, including several
instances, in which alternative splicing changes are known to
impact Th cell function [19]. Differential pre-mRNA splicing
generates structural and functional diversities that contribute
to various physiological processes such as differentiation into
distinct lineages of Th cells.
In this study, we report the identification and characteri-
zation of a novel alternatively spliced isoformof SLAT, named
SLAT2, which lacks the region encoded by exons 2–7 of the
Def6 gene. SLAT2 protein was expressed in differentiated
Th2 cells after two rounds of in vitro stimulation, but
not in differentiated Th1, Th17, and Treg cells. Similar to
SLAT, SLAT2 enhanced TCR-mediated activation of NFAT
and production of IL-4, but unlike SLAT [16] it was not
required for TCR-induced adhesion to intercellular adhesion
molecule-1 (ICAM-1). Ectopic expression of SLAT2 or SLAT
in Jurkat T cells resulted in the expression of distinct forms of
filopodia, namely, short versus long ones, respectively. Thus,
SLAT2 in differentiated Th2 cells appears to exhibit distinct
biological properties by comparison with SLAT. Differential
expression of SLAT2 or SLAT protein could thus play crit-
ical roles in cytokine production and actin reorganization
during inflammatory immune responses, leading to altered
functional activities of these regulators.
2. Materials and Methods
2.1. Mice. OT-II TCR-transgenic mice (The Jackson Labo-
ratory, Bar Harbor, ME) and C57BL/6N (B6) mice (Kyudo,
Saga, Japan) were purchased and kept under specific
pathogen-free conditions in the animal facility of Fukuoka
Dental College. 6- to 8-week-old mice were used in all
experiments. All experiments were performed in accordance
with the guidelines of the committee of Ethics of Animal
Experiments of Fukuoka Dental College.
2.2. Cell Culture and Stimulation. CD4+ T cells were puri-
fied from lymph node and spleen cells by magnetic sort-
ing using Dynabeads Mouse CD4 followed by treatment
with DETACHaBEAD Mouse CD4 (both from Invitrogen).
Splenic antigen-presenting cells (APCs) from B6 mice were
prepared by depletion of T cells through the use of CD90.2
MicroBeads Mouse (Miltenyi Biotec) and were treated with
mitomycin C before use. CD4+ T cells (5 × 105 per well)
from OT-II or B6 mice were cultured in a 24-well plate with
T cell-depleted, mitomycin C-treated B6 spleen cells (5 ×
106 per well) in a total volume of 2mL in the presence of
1 𝜇g/mL ovalbumin (OVA)323–339 peptide or 1 𝜇g/mL anti-
CD3 antibody (Ab) (145-2C11; BD), respectively. Th1 cells
were cultured by the addition of 10𝜇g/mL anti-IL-4Ab (11B11;
BD) and 10U/mL recombinant murine IL-12 (Peprotech).
Th2 cells were initiated by the addition of 10𝜇g/mL anti-IL-
12 Ab (C17.8; BD), 10𝜇g/mL anti-IFN𝛾 Ab (XMG1.2; BD),
and 100U/mL recombinant murine IL-4 (Peprotech). Th17
or Treg cells were differentiated in the presence of 2 ng/mL
recombinant human TGF-𝛽1 (R&D system) and 20 ng/mL
recombinant murine IL-6 (Peprotech), or in the presence of
2 ng/mL recombinant human TGF-𝛽1 and 2 ng/mL recom-
binant murine IL-2 (Peprotech), respectively. After 5 days,
differentiated T cells subsets (1 × 106 per well) were washed
and restimulated using 1 𝜇g/mL anti-CD3 Ab- plus 1 𝜇g/mL
anti-CD28 Ab (37.51; BD)-coated plates.
2.3. Cloning of the Gene Encoding SLAT2. CD4+ T cells from
B6 mice were cultured under Th2-inducing conditions and
then restimulated with plate-bound anti-CD3 Ab (1𝜇g/mL)
and anti-CD28 Ab (1 𝜇g/mL) for 2 days. The cells were
harvested and total RNA was isolated using an RNeasy
Kit (Qiagen). The RNA was reverse-transcribed into cDNA
by oligo (dT) priming with the SuperScript III reverse
transcriptase (Invitrogen). RT-PCR was performed with
the primers 5󸀠-ATGGCCCTGCGCAAGGAGCT-3󸀠 and 5󸀠-
CTAATTCCCTGGTGCTGGAT-3󸀠 and the amplified frag-
ment having ∼750 bp was cloned into the pGEM-T easy
vector (Promega).
2.4. Plasmid Constructs. SLAT cDNA was cloned into the
pEF-Myc-HisA vector (empty vector), resulting in the pEF-
SLAT-Myc plasmid, as described previously [3]. SLAT2
cDNA was cloned into the EcoRI and NotI sites of pEF-Myc-
HisA vector, giving rise to the pEF-SLAT2-Myc plasmid. A
DNA fragment encoding the FLAG epitope (DYKDDDDK)
was cloned into the XhoI and XbaI sites of pcDNA4/V5His-
A, resulting in the pcDNA-FLAG plasmid. SLAT and SLAT2
cDNAswere PCR-amplified and cloned into the SalI andNotI
sites of pcDNA-FLAG, fused in frame with the FLAG tag at
their 3󸀠 termini, yielding the plasmids pcDNA-SLAT-FLAG
and pcDNA-SLAT2-FLAG, respectively. A PCR-amplified
enhanced GFP (eGFP) gene was cloned into the NheI and
SalI sites of the pSI vector to result in the plasmid pSI-
EGFP. DNA fragments encoding SLAT-FLAG and SLAT2-
FLAG were PCR-amplified from plasmids pcDNA-SLAT-
FLAG and pcDNA-SLAT2-FLAG, respectively, and cloned
into the SalI and NotI sites of pSI-EGFP, giving rise to
the plasmids pSI-EGFP-SLAT-FLAG and pSI-EGFP-SLAT2-
FLAG, respectively. SLAT cDNA was cloned into the retro-
viral vector pMIG, resulting in a pMIG-SLAT plasmid,
as described previously [3]. SLAT2 cDNA was cloned
into the BglII site of pMIG vector, resulting in plasmid
pMIG-SLAT2.
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2.5. Cell Transfection and Western Blotting Analysis. SV40
large T antigen-transfected human leukemic Jurkat T cells
(Jurkat-TAg) in logarithmic growth phase were transfected
with plasmid DNAs by electroporation using NEPA21 Super
Electroporator (NEPAGENE, Japan). For detection of SLAT
and SLAT2 proteins, the samples were separated by 11% SDS-
PAGE, transferred to a PVDF membrane, and immunoblot-
ted with anti-SLAT antisera prepared as described [3],
anti-Myc Ab (9E10; Sigma), anti-GFP Ab (sc-9996; Santa
Cruz Biotechnology), or anti-actin Ab (sc-1616; Santa Cruz
Biotechnology). The signal intensity of SLAT and SLAT2
was quantified relative to the actin control using ImageJ
software.
2.6. Luciferase Reporter Assay. Jurkat-TAg cells were
transfected with an NFAT-luciferase plasmid plus a 𝛽-
galactosidase (𝛽-gal) reporter plasmid as described [20, 21].
After washing twice with phosphate-buffered saline (PBS),
transfected cells were lysed in 100 𝜇L of lysis buffer (pH
7.8, 0.5% Triton X-100, 1mM DTT, and 100mM KPO
4
) for
10min at room temperature. The lysate were centrifuged
(12,000×g) for 10min at 4∘C. After centrifugation, 20 𝜇L of
the supernatants was added with 50 𝜇L of Luciferase Assay
Substrate (Promega). Luciferase activity was determined in
a luminometer (GloMax 20/20 Single Tube Luminometer,
Promega). Each group of luciferase activity was normalized
to the cotransfected 𝛽-gal reporter activity.
2.7. Retroviral Transduction and Intracellular Cytokine Stain-
ing. Retroviral transduction was performed as described
[22]. Briefly,Th2 cells were differentiated underTh2-inducing
conditions by culture with T cell-depleted, mitomycin C-
treated B6 spleen cells (5 × 106) in the presence of 1𝜇g/mL
anti-CD3 for 5 days. The plasmids (10 𝜇g) were transfected
into Platinum-E packaging cells using X-tremeGENE 9 DNA
transfection reagent (Roche). The retroviral supernatants
were harvested 48 h after transfection, supplemented with
4 ng/mL recombinant murine IL-2 (Peprotech) and 5𝜇g/mL
Polybrene (Sigma-Aldrich), and used to infect the differenti-
atedTh2 cells that had been stimulatedwith plate-coated anti-
CD3 plus -CD28 monoclonal antibodies (mAbs) (1 𝜇g/mL
each) for 18 h after depletion of dead cells by Lympholyte-
M (Cedarlane). After centrifugation for 1 h (800×g, room
temperature), plates were incubated for 8 h at 32∘C and for
16 h at 37∘C. Two additional retroviral infections were carried
out at daily intervals.One day after the last retroviral infection
(day 4), IL-4 producing cells were analyzed by intracellular
cytokine staining (ICS). ICS was performed as described
[3]. Briefly, Th2 cells were restimulated with plate-bound
anti-CD3 plus -CD28 mAbs (1𝜇g/mL each) for 8 h in the
presence of 10 𝜇g/mL brefeldin A (Sigma-Aldrich) during the
final 2 h of culture. The stimulated cells were fixed in 3.7%
paraformaldehyde (Wako) for 10min at room temperature.
The fixed cells were permeabilized with PBS containing 0.5%
bovine serum albumin (BSA) plus 0.5% saponin (Sigma-
Aldrich) and stained with PE-conjugated anti-IL-4 Ab (11B11;
BD) for 30min. After washing twice with PBS containing
0.5% BSA and 0.5% saponin, the stained cells were analyzed
using a FACSCalibur (BD). Data were analyzed with FlowJo
software.
2.8. Adhesion Assay. Adhesion to ICAM-1 was performed
as described [16] with slight modification. Briefly, 5𝜇g/mL
goat anti-human-IgG (Fc) Ab (Jackson ImmunoResearch)-
immobilized plates were coated with 1 𝜇g/mL fusion protein
(Fc-ICAM-1) of recombinant mouse ICAM-1 and human
IgG1 Fc fragment (R&D Systems) overnight at 4∘C. The
coated plates were blocked with 1% BSA in PBS for 1 h at
room temperature. Transfected cells were labeledwith 2.5𝜇M
Calcein-AM (DOJINDO) for 30min at 37∘C in Phenol-Red-
free Hanks’ balanced salt solution, washed twice, and incu-
bated (1 × 105) on Fc-ICAM-1-coated plates, in the absence
or presence of 10𝜇g/mL anti-CD3 Ab (OKT3; Biolegend).
Obtained specific adhesion was expressed as a percentage of
output fluorescence divided by input fluorescence.
2.9. Confocal Microscopy. Transfected Jurkat-TAg cells were
placed on poly-L-lysine-coated coverslips with or without
2 𝜇g/mL anti-CD3 Ab (OKT3; Biolegend) for 30min at
37∘C, fixed in 4% paraformaldehyde for 10min at room
temperature, and stained with Alexa Fluor 546 phal-
loidin (Thermo Fisher Scientific) and 4󸀠,6󸀠-diamidino-2-
phenylindole (DAPI) (DOJINDO) for 40min at room tem-
perature. Images were captured with a LSM710 confocal laser
scanning microscope (Carl Zeiss, Germany) with a 100x/1.40
Oil DIC objective.
2.10. Statistical Analysis. Statistical analysis was performed
by using two-tailed Student’s t-test.
3. Results
3.1. Identification of a Novel SLAT Splice Variant. To examine
the expression of SLAT during Th2 differentiation, B6 naive
CD4+ T cells were activated in vitro under Th2-inducing
conditions. Western blotting analysis using an anti-SLAT Ab
revealed an unexpected smaller size SLAT-related molecule
in differentiated Th2 cells, but not in differentiated Th1 cells,
two days after the second round of in vitro stimulation
(Figure 1(a)). To better characterize this gene product, we
performed an RT-PCR on cDNA derived fromTh2 cells two
days after the second round of stimulation using primers
designed to amplify the entire SLAT open reading frame
(ORF). This resulted in amplification of a ∼750 bp product
revealed after a short (10 s) extension reaction, at which time
the PCR product corresponding to the full length SLAT
cDNA was not evident (Figure 1(b)). The ∼750 bp PCR
product was subcloned and sequenced, revealing a previously
unreported Def6 ORF, in which exons 2–7 were absent and
exon 1 was directly spliced to exon 8 without frameshifts.This
ORF potentially encodes a mature peptide comprising 257
amino acids. Western blotting analysis revealed that Jurkat-
TAg cells transfected with the alternatively spliced SLAT
cDNA expressed, as expected, a protein with a molecular
mass of ∼35 kDa, designated as SLAT2, in primary differ-
entiated Th2 cells after the second round of stimulation.
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Figure 1: Identification of SLAT2, a novel SLAT splice variant. (a) CD4+ T cells from B6mice were differentiated underTh1- orTh2-inducing
conditions with spleen-derived APCs and anti-CD3 Ab for 5 days, and the cells were then restimulated with plate-bound anti-CD3 plus
-CD28 mAbs. Cell lysates were prepared at the indicated days and analyzed by Western blotting using anti-SLAT Ab. Data are representative
of three independent experiments. (b) Gel electrophoresis of RT-PCR products amplified fromTh2 cells two days after the second round of
stimulation using primers spanning the entire SLAT open reading frame. Arrows indicate the position of SLAT2 (lower) or a predictable full
length SLAT (upper). (c) Expression of SLAT and SLAT2 proteins in differentiatedTh2 cells and Jurkat-TAg cells transfected with pEF-SLAT
or pEF-SLAT2. DifferentiatedTh2 cells from B6 mice were restimulated with plate-bound anti-CD3 plus -CD28 mAbs for 4 days. Cell lysates
were analyzed by anti-SLAT or anti-Myc immunoblotting. Data are representative of three independent experiments. (d) Genomic structure
of SLAT and the alternatively spliced isoform SLAT2. Primers used for PCR amplification are indicated with arrows. Exons and introns are
shown as open boxes and lines, respectively. SLAT2 contains the DH-like domain but lacks the part of EF-hand and the entire ITAM-like
sequence and PH domain.
In contrast, SLAT-transfected cells expressed a protein of
∼75 kDa (Figure 1(c)). Residues 33–257 are identical to the
DH domain of SLAT. Primary structures of SLAT and SLAT2
are shown in Figure 1(d).
3.2. Expression and Regulation of SLAT2. To determine the
kinetics of SLAT2 protein expression, B6 naive CD4+ T
cells differentiated under Th2- or Th1-inducing conditions
were restimulated on day 5 with plate-coated anti-CD3 plus
-CD28 mAbs under neutral culture conditions (Figure 2(a)).
Prior to restimulation (day 0), SLAT2 was not expressed
in either Th2 or Th1 cells, while SLAT was expressed in
Th2, but not (or substantially less) in Th1 cells. Importantly,
restimulation led to a substantial upregulation of SLAT2
protein expression on day 2 in Th2 cells, but not in Th1 cells.
This upregulation was sustained on day 4 and decreased by
day 6. In contrast, upregulation of SLAT was not observed
on day 2 but was evident on days 4 and 6 in Th2 cells. To
evaluate the expression of SLAT2 and SLAT under conditions
of specific antigen stimulation, we obtained naive CD4+ T
cells from OT-II TCR-transgenic mice, which express an
OVA-specific TCR, and cultured the cells with a low dose of
OVA peptide and splenic APCs from B6 mice under Th2- or
Th1-inducing conditions. Similar to B6 Th cells, SLAT2 was
not expressed during the initial round of OVA stimulation
(data not shown). However, following the second round of
stimulation, the expression of SLAT2 was induced within one
day reaching a maximum on day 2, with no SLAT2 detected
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Figure 2: Kinetics of SLAT2 expression in differentiated Th cells. (a) CD4+ T cells from B6 mice were differentiated under Th1- and Th2-
inducing conditions as in Figure 1. Cell lysates were prepared at the indicated days and analyzed by Western blotting using anti-SLAT
Ab. Numbers under the SLAT blot indicate intensity of SLAT and SLAT2 signals relative to SLAT signal of Th2 cells on day 0 (=1) after
normalization to the actin signal. (b) CD4+ T cells from OT-II mice were differentiated under Th1- or Th2-inducing conditions with splenic
APCs and 1 𝜇g/mL OVA323–339 peptide for 5 days, and the cells were further restimulated with plate-bound anti-CD3 plus -CD28 mAbs. Cell
lysates were prepared at the indicated days and analyzed as in (a). (c) CD4+ T cells from B6 mice were differentiated into the indicated Th
cell subset and restimulated with splenic APCs and anti-CD3 Ab for 4 days. Cell lysates were analyzed byWestern blotting as in (a). Data are
representative of at least two independent experiments.
after 0.5 days of stimulation (Figure 2(b)). Next, we examined
the expression of SLAT2 in other subsets of differentiatedTh
cells, namely, Th17 and Treg cells. SLAT2 was observed in
restimulated Th2 cells, but not in differentiated Th1, Th17, or
Treg cells (Figure 2(c)). In contrast, SLATwas expressed in all
subsets of differentiated Th cells. These results indicate that
the expression of SLAT2 in differentiated and restimulated T
cells is unique to theTh2 subset.
3.3. SLAT2 Enhances TCR-Induced NFAT Activity and IL-4
Expression. SLAT promotes Th1 and Th2 cell differentiation
by controlling NFAT activation in CD4+ T cells [17] and
enhances TCR-induced NFAT activity [11]. To understand
the function of SLAT2, we examined the effect of ectopic
SLAT2 versus SLAT expression on the TCR-induced acti-
vation of an NFAT-luciferase reporter gene in Jurkat-TAg
cells. Similar to SLAT and as previously shown [11], SLAT2
induced a dose-dependent increase in NFAT activity relative
to empty vector-transfected cells (Figure 3(a)). Thus, SLAT2
can enhance the TCR-induced NFAT activity, just like SLAT.
Next, we determined whether additional SLAT2 expression
enhanced SLAT-mediated NFAT activity under TCR stimu-
lation. Importantly, SLAT2 had an additive effect combined
with SLAT on the TCR-induced NFAT activity (Figure 3(b)).
These results suggest that the activation of TCR-induced
NFAT is enhanced by SLAT2 and/or SLAT in Jurkat T cells.
NFAT activation promotes the expression of IL-4 in
Th2 cells [23, 24]. To explore whether SLAT2 can regulate
the production of IL-4, we generated a retroviral SLAT2
expression vector (Figure 3(c)), which was used to infect dif-
ferentiated Th2 cells, resulting in a transduction efficiency of
25%–45% (data not shown). We have previously shown that
transduction of differentiated Th2 cells with SLAT increases
the fraction of IL-4-producing cells in the GFP+ population
[3]. Importantly, under the same conditions SLAT2 increased
the fraction of IL-4-producing cells, that is, from ∼39% to
∼55% IL-4+ cells (Figure 3(d)), even though SLATminimally
increased the fraction of IL-4-producing cells from ∼39%
to ∼43% (Figure 3(d)). These results indicate that SLAT2
increases the level of IL-4-producing cells by differentiated
Th2 cells.
3.4. SLAT2 Is Not Required for TCR-Induced Adhesion to
ICAM-1. SLAT promotes the TCR-induced adhesion of T
cells to ICAM-1 via leukocyte function-associated antigen-
1 (LFA-1) activation [16]. To explore the role of SLAT2 in
regulating LFA-1 function following TCR engagement, we
examined the effect of ectopic SLAT2 expression on the TCR-
mediated adhesion to ICAM-1. SLAT-transfected Jurkat-TAg
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Figure 3: SLAT2 enhances TCR-induced NFAT activity and IL-4 expression. (a and b) Jurkat-TAg cells (5 × 106) were cotransfected with the
indicated plasmid cDNA amounts of empty vector or SLAT and/or SLAT2 together with NFAT-Luc (5𝜇g) and 𝛽-galactosidase (𝛽-gal) (5 𝜇g)
reporter plasmids. The cells were left unstimulated or were stimulated with 2 𝜇g/mL anti-CD3 Ab (OKT3) for 6 h at 37∘C. Luciferase activity
was normalized to the activity of 𝛽-gal and data are displayed as % NFAT activity relative to basal activity in unstimulated cells (=100%).
Data represent means of triplicates, and graphs show means ± SD. Statistical analysis was performed using Student’s t-test (∗𝑃 < 0.01;
∗∗
𝑃 < 0.001). Expression of transfected SLAT and SLAT2 or endogenous actin proteins was detected by Western blotting (bottom panels).
Data are representative of three independent experiments. (c) Schematic diagram of retroviral SLAT and SLAT2 constructs in the pMIG
vector. (d) Five-day differentiatedTh2 cells were restimulated with anti-CD3 plus -CD28 mAbs and infected with the indicated retroviruses.
Cells were harvested on day 9 (4 days after second stimulation), restimulated with anti-CD3 plus -CD28mAbs, and IL-4-producing cells were
enumerated by intracellular cytokine staining. Data are representative of two independent experiments.
cells showed an increase in TCR-induced adhesion to ICAM-
1 relative to control transfectants, as previously shown [16].
In contrast, SLAT2 had no effect on TCR-induced adhesion
to ICAM-1 (Figure 4(a)). Thus, unlike SLAT, SLAT2 does
not appear to enhance TCR-induced adhesion to ICAM-1 in
T cells. These results suggest that SLAT2 may function in
a manner different from SLAT during TCR-mediated T cell
activation.
3.5. SLAT2 Localizes within Cytoplasm and Induces Short
Filopodia. It is known that SLAT localizes to the plasma
membrane and spreads diffusely throughout the cytoplasm in
COS-7 cells [10, 13, 25]. To determine the cellular distribution
of SLAT2, GFP-tagged SLAT2 or SLAT was expressed with
Alexa Fluor 546-labeled phalloidin in Jurkat-TAg cells. The
intracellular location of the proteins was determined by
confocal microscopy. GFP-SLAT was found to colocalize
International Journal of Inflammation 7
SLAT2Vector SLAT
(a)
(c)(b)
150
100
75
50
37
25
20
Ve
ct
or
SL
AT
SL
AT
2
Anti-SLAT Ab
Anti-actin Ab
(kDa)
SLAT
SLAT2
Actin5037
150
100
75
50
37
25
20
Ve
ct
or
SL
AT
SL
AT
2
Anti-Myc Ab
(kDa)
SLAT
SLAT2
Ve
ct
or
SL
AT
SL
AT
2
Anti-SLAT Ab
Anti-actin Ab
(kDa)
GFP-
GFP-
Actin50
37
150
100
75
50
37
25
20
Ve
ct
or
SL
AT
SL
AT
2
Anti-GFP Ab
(kDa)
150
100
75
50
37
25
20
GFP
SLAT
SLAT2
GFP-
GFP-
SLAT
SLAT2
SLATVector
NS
w/o
CD3
∗
SLAT2
0
5
10
15
Ad
he
sio
n 
to
 IC
A
M
-1
 (%
)
Long lopodia
Short lopodia
No lopodia
CD3w/o w/o CD3
Vector
w/o CD3
SLAT SLAT2
∗∗
∗∗
0
20
40
60
80
100
120
C
ell
s (
%
)
Figure 4: Effect of SLAT2 expression on T cell adhesion and filopodia formation. (a) Jurkat-TAg cells (5 × 106) were transfected with empty
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performed using Student’s t-test (∗∗𝑃 < 0.001). Scale bar, 10 𝜇m. Data are representative of three independent experiments.
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with F-actin at the plasma membrane with or without
TCR stimulation and, furthermore, compared to the empty
vector-transfected cells, GFP-SLAT expression resulted in an
apparent formation of long filopodia in Jurkat T cells in
unstimulated T cells, and anti-CD3 stimulation caused a fur-
ther increase (Figure 4(b), middle panel). In contrast, GFP-
SLAT2 localized within the cytoplasm but did not colocalize
with F-actin near the plasma membrane. Furthermore, GFP-
SLAT2 mostly induced short filopodia formation in Jurkat T
cells in either the absence or presence of TCR stimulation
(Figure 4(b), right panel). In the control cells, faint short
filopodia formation was observed in some GFP-transfected
Jurkat-TAg cells. Quantitation of filopodia formation in the
transfected T cells (Figure 4(c)) revealed that ectopic GFP-
SLAT2 protein increased short filopodia formation in TCR-
stimulated cells (17.3% ± 2.1% in GFP-SLAT-transfected
cells versus 64.7% ± 3.5% in GFP-SLAT2-transfected cells;
𝑃 < 0.001). In contrast to SLAT2, GFP-SLAT preferentially
mediated long filopodia formation (70.7% ± 2.5% in GFP-
SLAT-transfected cells versus 5.7% ± 2.1% in GFP-SLAT2-
transfected cells; 𝑃 < 0.001). These results indicate that,
unlike SLAT, SLAT2 expression augments short filopodia
formation at the expense of long filopodia in stimulated T
cells.
4. Discussion
Alternative splicing is an important mechanism for con-
trolling gene expression and increasing protein diversity
from a single primary transcript. In the immune system,
alternative splicing allows large proteomic complexity from a
limited number of genes in inflammatory immune regulation
network. Indeed, a few recent notable examples of alterna-
tive splicing, in CD4+ T cell-expressed mucosa-associated
lymphoid tissue protein 1 (MALT1) [26] and Foxp3 [27],
have been demonstrated to regulate T cell responses to
antigen [19]. In the present study, we have identified a new
alternatively spliced product, termed SLAT2, of the murine
Def6 gene in differentiated Th2 cells after the second round
of stimulation. SLAT2 mRNA is generated by the splicing of
exons 2–7 that results in a partial deletion of Ca2+-binding
EF-hand and in the complete deletion of the ITAM-like
sequence and the PH domain, generating a correct reading
frame and a translated product that contains the C-terminal
DH domain. The selective and transient upregulation of
SLAT2 induced in differentiated Th2 cells by TCR restimu-
lation suggests that SLAT2 may play a role in Th2-mediated
immune responses, for example, allergic lung inflammation.
NFAT, a major regulator of T cell activation, is critical
for IL-4 production andTh2 differentiation [23, 24]. Increas-
ing evidence indicates that SLAT, which is predominantly
expressed in T cells, plays important roles in TCR-mediated
signaling by linking actin cytoskeleton reorganization and
Cdc42 activation to the Ca2+-NFAT signaling pathway and
consequently to Th cell differentiation during inflammation
[11, 12, 17, 28]. Our recent study demonstrated that the N-
terminal EF-hand domain and the PH domain of SLAT
interact with inositol 1,4,5-triphosphate receptor type 1 and
that this interaction is important for TCR-mediated Ca2+-
NFAT signaling [15]. Interestingly, SLAT2 still possessed the
ability to enhance NFAT activation, and coexpression of
SLAT2 with SLAT resulted in further enhancement of TCR-
inducedNFATactivation despite the fact that SLAT2 lacks the
ITAM-like sequence and PH domain, which were previously
shown to contribute to the Ca2+-NFAT signaling function of
SLAT [11]. In addition, confocal microscopy analysis showed
that SLAT2 did not translocate to the plasmamembrane upon
TCR stimulation. We therefore propose that cytosolic SLAT2
can enhance Ca2+-NFAT signaling in a different way from
SLAT or it may be able to act additively to SLAT in this
pathway. We have also provided evidence that ectopic SLAT2
expression enhances the production of IL-4, in differentiated
Th2 cells.Thus, the enhancement of NFAT activation induced
by SLAT2 could account for the increased IL-4 expression by
SLAT2-transducedTh2 cells.
SLAT2 expression was transiently and selectively upregu-
lated in differentiated Th2 cells within one day of the second
TCR stimulation, reached a maximum after two days, and
declined by the sixth day, even though upregulation of SLAT2
was not observed during the first stimulation at all. SLAT2
is therefore expressed at a relatively late stage of Th cell
differentiation, suggesting that it may not contribute to early
Th2 cell differentiation per se, but may function during the
effector phase of Th2 cell function. Differentiated Th2 cells
transcribe Il4 as early as 1 day after TCR restimulation (data
not shown), a time when SLAT2 was already substantially
upregulated. Further work should be aimed at defining
the precise mechanisms that regulate the enhanced IL-4
expression by SLAT2 in differentiated Th2 cells, including in
vivo, during inflammation.
Some of SLAT functions were not observed in SLAT2,
including adhesion to ICAM-1 that reflects LFA-1 activation,
and longfilopodia formation in Jurkat T cell. SLAT is involved
in TCR-induced adhesion through interaction of its PH
domain with Rap1 GTPase, which was required for T cell
adhesion to ICAM-1 [16]. Therefore, the deletion of the PH
domain in SLAT2 likely explains the inability of SLAT2 to
promote adhesion to ICAM-1. Thus, the functions of SLAT2
seem to be distinct from those of SLAT in TCR-mediated
activation. SLAT is expressed and functions not only in Th
cells but also in other types of cells, such as macrophages [29,
30], osteoclasts [31], and cancer cells [32–35]. Thus, it would
be interesting to determine whether SLAT2 is expressed and
functions in these other cell types.
Cdc42 member of the Rho family of small GTPases is
cytosol in its GDP-bound resting form. Cdc42 functions as
a molecular switch by cycling between GDP-bound inactive
and GTP-bound active states and is recruited to membranes
where its GDP is exchanged for GTP through the action
of several GEFs with known reactivity toward Rho family
GTPases [36]. Dbl family proteins, which possess a cat-
alytic DH domain followed by a PH domain, constitute
the largest subgroup of Rho-specific GEFs, followed by the
dedicator of cytokinesis (DOCK) family, whose members
possess a DOCK homology region 2 (DHR2) instead of a
DH domain. The smallest subgroup of SWAP-70 subfamily
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includes SWAP-70 and SLAT, which contain a DH-like
domain but neither a DH nor a DHR2 domain. Some of these
Rho GEFs, that is, Vav [22] and 𝛽PIX [37] (Dbl subfamily),
DOCK8 [38] (DOCK subfamily), and SLAT [3, 9–14, 39–
42] (SWAP-70 subfamily), participate in TCR signaling and
Th cell differentiation and are known to mediate GEF activ-
ity on Cdc42. The SLAT DH-like domain possesses TCR-
mediated, plasma membrane-residing GEF activity toward
Cdc42 that controls dynamics of the actin cytoskeleton and
leads to long filopodia formation [10]. Additionally, the TCR-
induced tyrosine phosphorylation of the ITAM-like sequence
in SLAT is required for its translocation to the plasma
membrane and immunological synapse [11]. We observed
lack of membrane localization of SLAT2, which correlated
with reduced long filopodia formation in SLAT2-transfected
T cells compared to SLAT-transfected cells. Instead, SLAT2
increased formation of short, rather than long, filopodia in
TCR-stimulated cells. Therefore, the differential localization
and function of the two SLAT proteins and, potentially,
differences in their reactivity toward Cdc42 might play an
important role in regulating the formation of filopodia at the
site of inflammatory immune responses.
5. Conclusions
Collectively, our results suggest that alternative splicing of
SLATmay exhibit differential biological activities upon TCR-
mediated stimulation and that modulating either SLAT2
or SLAT protein expression could play critical roles in
cytokine production and actin reorganization during inflam-
matory immune responses, leading to altered functional
activities of these regulators. Precise understanding of
the mechanism through which SLAT2 modulates TCR-
mediated signaling and Th2 cell function awaits future
studies.
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